The pharmacological effect of hexoketococine can depend on the effect of reducing the viscosity of blood, increasing the denaturation of red blood cells, improving the hemodynamic properties of white blood cells, and the ability to inhibit the adhesion and activation of neutrophils. In patients suffering from chronic peripheral arterial vascular disease, this drug increases blood flow, affects microcirculation, and improves oxygenation of tissues. This drug is not bound to plasma proteins and is mainly metabolized by the liver and excreted through the kidneys. The elimination half-life of its prodrug and metabolites is about 0.5 or 1.5 hours, and the clotting time is prolonged when it is combined with antiplatelet or anticoagulant drugs during the course of drug administration. The dose should be reduced when combining this drug in patients on warfarin. There is a synergistic effect when combined with theophylline drugs.